Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.

RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...

PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587), announced the achievement of a preclinical development milestone in ...

Ten of the twelve former Food and Drug Administration (FDA) commissioners and acting commissioners opposed to the Trump ...

Halozyme Therapeutics, Inc. (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPROtm (amivantamab and ...

Mega-cap technology companies have come to embody America’s market might: innovative, dominant, and seemingly unstoppable.

Despite market gains, Harbor Long-Term Growers ETF returned 6.90% (NAV) in Q3. Read the full report to understand key drivers ...

Harbor Long Term Growers ETF returned 6.90% in Q3 2025, underperforming its benchmark. Read the full report to discover key ...

Kane Biotech Inc. (the "Company", "Kane" or "Kane Biotech") announces that today it has completed its previously announced non-brokered private placement offering (the "Offering") of common shares of ...

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. -- Vir Biotechnology's chronic hepatitis delta ...

The macro and thematic equity research group founded by investor and trend spotter James van Geelen saw positive returns - up to 75% - on nearly all of their 2025 calls. Their electronic warfare ...